This file is part of IDEAS, which uses RePEc data


[ Papers | Articles | Software | Books | Chapters | Authors | Institutions | JEL Classification | NEP reports | Search | New papers by email | Author registration | Rankings | Volunteers | FAQ | Blog | Help! ]

The Evolution of the French Public Policy to Promote Biotech Innovation : The Case of Genomics

Author info | Abstract | Publisher info | Download info | Related research | Statistics
Author Info
Anne Branciard () (LEST - Laboratoire d'économie et de sociologie du travail - CNRS : UMR6123 - Université de Provence - Aix-Marseille I - Université de la Méditerranée - Aix-Marseille II)
Vincent Mangematin

Additional information is available for the following registered author(s):

Abstract

European Biotechnology companies and public policy-makers face to a number of crucial problems related to the development of Biotechnology in Europe : European industrial competitiveness, the relative under-exploitation of the European science base in Biotechnology, poor technology transfer mechanisms and difficulties in starting 'spin-off' firms. The aim of this paper on innovation in genomics and biomedical related biotechnologies is to study the relative impact of the different public policy in France compared to the action of the private non for profit sector. Public policies in favour of biotech have changed during the last ten years from a support of research in large firms to a support of SME's creation in biotech. At the same time, large non-for profit organisations such as CEPH (Human Polymorphism Research Center) and AFM (French Organisation Against Myopaty) create a new dynamic by initiating path breaking scientific and technical programmes. This new scientific space has been complementary to the public policy, but only to a certain extend. By studying the co-ordination mechanisms between the different organisations (non for profit organisations, public authorities, public sector research, Biotech SMEs and large firms, especially in the biomedical sector), this paper shows that the existing contradiction between the different tools to encourage biotech economic development can explain the poor development of biotech sector in France in the last few years. It also shows that the situation is getting better the last two years, especially in terms of firms' creation.

Download Info
To download:

If you experience problems downloading a file, check if you have the proper application to view it first. Information about this may be contained in the File-Format links below. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.

File URL: http://halshs.archives-ouvertes.fr/docs/00/12/54/14/PDF/art_AB-VM_2001.pdf
File Format: application/pdf
File Function:
Download Restriction: no

Publisher Info
Paper provided by HAL in its series Post-Print with number halshs-00125414_v1.

Download reference. The following formats are available: HTML (with abstract), plain text (with abstract), BibTeX, RIS (EndNote, RefMan, ProCite), ReDIF
Length:
Date of creation: 2001
Date of revision:
Handle: RePEc:hal:journl:halshs-00125414_v1

Note: View the original document on HAL open archive server: http://halshs.archives-ouvertes.fr/halshs-00125414/en/
Contact details of provider:
Web page: http://hal.archives-ouvertes.fr/

For technical questions regarding this item, or to correct its listing, contact: (CCSD).

Related research
Keywords: Public Policy; Research Policy; Biotechnology; Innovation; R&D; SME;

Statistics
Access and download statistics

Did you know? You can include your works in the database easily by uploading them on the Munich Personal RePEc Archive (MPRA) if you do not have access to an institutional RePEc archive.

This page was last updated on 2009-12-22.


This information is provided to you by IDEAS at the Department of Economics, College of Liberal Arts and Sciences, University of Connecticut using RePEc data on a server sponsored by the Society for Economic Dynamics.